Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
抗C5a抗体（vilobelimab）疗法治疗重症COVID-19患者（需有创机械通气）(PANAMO)：一项多中心、双盲、随机、安慰剂对照的3期临床试验
期刊:Lancet Respiratory Medicine
影响因子:32.8
doi:10.1016/S2213-2600(22)00297-1
Vlaar, Alexander P J; Witzenrath, Martin; van Paassen, Pieter; Heunks, Leo M A; Mourvillier, Bruno; de Bruin, Sanne; Lim, Endry H T; Brouwer, Matthijs C; Tuinman, Pieter R; Saraiva, José F K; Marx, Gernot; Lobo, Suzana M; Boldo, Rodrigo; Simon-Campos, Jesus A; Cornet, Alexander D; Grebenyuk, Anastasia; Engelbrecht, Johannes M; Mukansi, Murimisi; Jorens, Philippe G; Zerbib, Robert; Rückinger, Simon; Pilz, Korinna; Guo, Renfeng; van de Beek, Diederik; Riedemann, Niels C
